

Heart Failure with Preserved Ejection Fraction

Albert J. Hicks III, MD, MPH

Assistant Professor

University of Maryland School of Medicine

Section Chief Advanced Heart Failure & Transplant

Medical Director Heart Transplant

Baltimore, MD



1

Disclosure

Consultant: Alnylam; Boehringer Ingelheim; BridgeBio

Speaker's Bureau: Alnylam; Boehringer Ingelheim;
BridgeBio




2

Objectives

- To gain a better understanding of the challenges associated with finding substantial treatments for HFpEF
- To be able to explain the pathophysiology of HFpEF
- To apply the limited therapies that improve QOL, exercise tolerance, and heart failure hospitalizations to their patients with HFpEF

3

Previous Description of Heart Failure



4

Circulation

Volume 145, Issue 18, 3 May 2022; Pages e895-e1032
<https://doi.org/10.1161/CIR.0000000000001063>

**AHA/ACC/HFSA CLINICAL PRACTICE GUIDELINE****2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines**

5

New Heart Failure Categories

HF with reduced EF (HFrEF)

- LVEF \leq 40%

HF with mildly reduced EF (HFmrEF)

- LVEF 41- 49%

HF with preserved EF (HFpEF)

- LVEF \geq 50

HF with improved EF (HFimpEF)

- Baseline LVEF \leq 40%, a \geq 10 pt increase in baseline LVEF, and a 2nd measurement of LVEF $>$ 40%

Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure [published online ahead of print, 2021 Mar 1]. *J Card Fail.* 2021;S1071-9164(21)00050-6. doi:10.1016/j.cardfail.2021.01.022

6

Early Description of HFpEF

Congestive Heart Failure with Normal Systolic Function

ANNE HAMILTON DOUGHERTY, MD, GERALD V. NACCARELLI, MD,
ELAYNE L. GRAY, BSN, CHARLES H. HICKS, MD, and RICHARD A. GOLDSTEIN, MD

Although there have been isolated reports of congestive heart failure (CHF) with normal systolic function, the prevalence and characteristics of this condition have not previously been described. Accordingly, 188 patients with CHF undergoing radionuclide ventriculography were prospectively evaluated. Sixty-seven (36%) had a normal ejection fraction (EF) of 0.45 or greater, and 121, an abnormal EF of less than 0.45. Of these, 72 (55 with an abnormal EF [group I] and 17 with a normal EF [group II]) were also reviewed for clinical characteristics. There was no demographic difference between groups, except that systemic hypertension appeared to be a contributing factor in 65% of the

patients in group II, compared with 23% of the patients in group I ($p < 0.002$). Echocardiographic left atrial emptying index, reflecting left ventricular compliance, was determined in 72 patients and 14 normal subjects. Left atrial emptying index in normal control subjects was 0.93 ± 0.11 (\pm standard deviation), compared with 0.41 ± 0.18 in group I and 0.44 ± 0.19 in group II patients ($p < 0.001$ vs control in both groups). Thus, normal systolic function is common among patients with CHF. Diastolic dysfunction, consistent with a noncompliant left ventricle, was found in both CHF groups.


(Am J Cardiol 1984;54:778-782)

7

Incidence of HFpEF Is Increasing

Tsao et al. *JACC: HF* 2018

N=15,217 (FHS, CHS); 60% women; 2,524 incident HF cases; 115,703 person-years of follow-up




- Higher rates of Diabetes, HTN, CKD, Obesity
- Greater number of Elderly population
- Increased awareness by providers

Tsao et al JACC HF 2018

8

Causes and Temporal Patterns of 30-Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction



Tsao et al JACC HF 2018

9

Causes and Temporal Patterns of 30-Day Readmission Among Older Adults Hospitalized With Heart Failure With Preserved or Reduced Ejection Fraction

Cause	HFpEF Readmissions (n=3075)	HFrEF Readmissions (n=3367)
	n (%)	n (%)
HF	743 (24.2)	1105 (32.8)
Non-HF cardiovascular-related	517 (16.8)	673 (20.0)
Dysrhythmia	139 (4.5)	142 (4.2)
Acute myocardial infarction	54 (1.8)	108 (3.2)
Coronary atherosclerosis	60 (2.0)	97 (2.9)
Hypertension with complications	77 (2.5)	89 (2.6)
Non-cardiovascular-related	1815 (59.0)	1589 (47.2)
Acute renal failure	168 (5.5)	167 (5.0)
Septicemia	160 (5.2)	155 (4.6)
Pneumonia	150 (4.9)	106 (3.1)
Adult respiratory failure	141 (4.6)	104 (3.1)
COPD	99 (3.2)	84 (2.5)
Fluid/electrolyte diagnosis	82 (2.7)	81 (2.4)
Urinary tract infection	73 (2.4)	60 (1.8)

Tsao et al JACC HF 2018

10

What Is HFpEF?

11

Pathophysiology of HFpEF

- LV diastolic *and* systolic dysfunction
- Vascular stiffening and abnormal ventricular-arterial coupling
 - Cardiac Output reduction during exercise
 - Markedly elevated filling pressures during exercise
- Chronotropic incompetence

Borlaug and Paulus Eur Ht J 2011


12

Exercise Intolerance in Patients With Heart Failure and Preserved Left Ventricular Systolic Function: Failure of the Frank-Starling Mechanism

DALANE W. KITZMAN, MD, MICHAEL B. HIGGINBOTHAM, MB, FREDERICK R. COBB, MD, KHALID H. SHEIKH, MD, MARTIN J. SULLIVAN, MD


Durham, North Carolina

The abnormalities in left ventricular diastolic function **limited patients' ability to augment stroke volume** by means of the Frank-Starling mechanism, resulting in **severe exercise intolerance**



Kitzman et al. JACC 1991

13



Kitzman et al. JACC 1991

14

HFpEF & CoMorbidity


- Advanced age, hypertension, obesity, female gender, anemia, diabetes, renal dysfunction, and impaired LV compliance have been either associated with the prevalence of HFpEF or the ventricular-vascular dysfunction seen in patients with HFpEF
- These comorbidities do not fully account for the poor outcomes seen in the HFpEF population

Ather S, Chan W, Bozkurt B, et al. **Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.** *J Am Coll Cardiol* 2012;59:998–1005.


Takeda Y, Sakata Y, Mano T, et al. **Competing risks of heart failure with preserved ejection fraction in diabetic patients.** *Euro J Heart Fail* 2011 Jun;13(6):664–9.

Mohammed SF, Borlaug BA, Roger VL, et al. **Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study.** *Circ Heart Fail* 2012;5:710–9.

15




16



17

HFpEF Remodeling Pathway

Shah S...Paulus W *Circulation* 2016


18

Medical Therapy for HFpEF

19

TOPCAT


Spironolactone vs. Placebo

1^o Endpoint: Composite of CV Death, Aborted Cardiac Arrest, or HF Hospitalization

Pitt et al. NEJM 2014


20

Regional Variation in Outcomes in TOPCAT



21

Regional Variation in Outcomes in TOPCAT



22

ORIGINAL ARTICLE

Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, S.A. Boytsov, J. Comin-Colet, J. Cleland, H.-D. Düngen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, and M.P. Lefkowitz, for the PARAGON-HF Investigators and Committees

N=4822

NYHA II-IV

EF ≥45%

Evidence of structural heart disease

Elevated levels of natriuretic peptides

Requiring chronic treatment with diuretics

Solomon S et al. NEJM 2019

23

PARAGON Sacubitril-Valsartan vs Valsartan in HFpEF

Methods


- 4822 pts Randomized
- NYHA Class II –IV
- LVEF ≥ 45%
- ↑ BNP
- 1° Endpoint
 - Total HHF + Death from CV Causes
- 2 Endpoints
 - Death from CV causes
 - Worsening Renal Function
 - Change in KCCQ
 - Safety

Results

- Valsartan-Sacubitril did not significantly reduce:
 - 1° endpoint of Total HHF+Death from CV causes (RR 0.87, CI 0.75–1.01, p 0.06)
 - 2° endpoint of Death from CV causes compared to Valsartan (8.5% VS 8.9%)
- Subgroup Analysis Sacubitril-Valsartan demonstrated improvement in 1 Endpoint compared to Valsartan in the following groups
 - Lower EF (<57%)
 - Women


Solomon S et al. NEJM 2019

24



25

Mechanisms of Preservation of CV and Renal Function in SGLT2-inhibition That May Benefit HFpEF

SGLT-2 inhibition^[a,b] Mechanism^[a-d]Cardio-renal effects^[e,f]Clinical outcomes^[g,h]

a. Heise T, et al. Diabetes Obes Metab 2013; b. Heise T, et al. Clin Ther 2016; c. Ferranini G et al. Diabetes Care 2015; d. Briand F, et al. Diabetes 2016; e. Heerspink HJ, et al. Circulation 2016; f. Inzucchi SE, et al. Diab Vasc Dis Res 2015; g. Zinman B, et al. NEJM 2015; h. Wanner C et al. NEJM 2016

26

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

OCTOBER 14, 2021


VOL. 385 NO. 16

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

S.D. Anker, J. Butler, G. Filippatos, J.P. Ferreira, E. Bocchi, M. Böhm, H.-P. Brunner-La Rocca, D.-J. Choi, V. Chopra, E. Chuquiere-Valenzuela, N. Giannetti, J.E. Gomez-Mesa, S. Janssens, J.L. Januzzi, J.R. Gonzalez-Juanatey, B. Merkely, S.J. Nicholls, S.V. Perrone, I.L. Piña, P. Ponikowski, M. Senni, D. Sim, J. Spinar, I. Squire, S. Taddei, H. Tsutsui, S. Verma, D. Vinereanu, J. Zhang, P. Carson, C.S.P. Lam, N. Marx, C. Zeller, N. Sattar, W. Jamal, S. Schnaidt, J.M. Schnee, M. Brueckmann, S.J. Pocock, F. Zannad, and M. Packer, for the EMPEROR-Preserved Trial Investigators*

27

EMPEROR Preserved




- 1st HFpEF medication to reach it's 1^o Endpoint
- CV Death or Hospitalization for HF
 - Empagliflozin Group 415 of 2997 pts (13.8%)
 - Placebo Group 511 of 2991 patients (17.1%) HR 0.79 (0.69 to 0.90); P<0.001
- NNT 31 pts for 36 months

Anker et al NEJM 2021

28

EMPEROR Preserved




RRR = 27%

Anker et al NEJM 2021


29

DELIVER- HF



30

DELIVER-HF



31

Semaglutide: STEP-HF

- 529 pts with HFpEF and Obesity (BMI >30)
- Placebo VS Semaglutide 2.4 mg weekly for 52 wks
- 1 Endpoint: Change in KCCQ-CSS
- 2 Endpoints:
 - 6-min walk distance
 - Composite of death, HF events, KCCQ-CSS diff, 6-min walk
 - C-Reactive Protein levels

Kosiborod et al NEJM 2023

32

Semaglutide: STEP-HF

Semaglutide Group VS Placebo Changes from Baseline

- KCCQ-CCS: 16.6 pts VS 8.7 pts
- Body Weight: -13.3% VS -2.6%
- 6 Min Walk: 21.5 m VS 1.2 m
- CRP Level: -43.5% VS -7.3%
- Serious Adverse Events: 13.3% VS 26.7%
- Composite: More wins with Semaglutide group (win ratio 1.72)

Kosiborod et al NEJM 2023

33


2022 ACC/AHA/HFSA HF Guidelines

COR	LOE	Recommendations
1	C-LD	1. Patients with HFpEF and hypertension should have medication titrated to attain blood pressure targets in accordance with published clinical practice guidelines to prevent morbidity. ¹⁻³
2a	B-R	2. In patients with HFpEF, SGLT2i can be beneficial in decreasing HF hospitalizations and cardiovascular mortality. ⁴
2a	C-EO	3. In patients with HFpEF, management of AF can be useful to improve symptoms.
2b	B-R	4. In selected patients with HFpEF, MRAs may be considered to decrease hospitalizations, particularly among patients with LVEF on the lower end of this spectrum. ⁵⁻⁷
2b	B-R	5. In selected patients with HFpEF, the use of ARB may be considered to decrease hospitalizations, particularly among patients with LVEF on the lower end of this spectrum. ^{8,9}
2b	B-R	6. In selected patients with HFpEF, ARNi may be considered to decrease hospitalizations, particularly among patients with LVEF on the lower end of this spectrum. ^{10,11}
3: No-Benefit	B-R	7. In patients with HFpEF, routine use of nitrates or phosphodiesterase-5 inhibitors to increase activity or QOL is ineffective. ^{12,13}

Heidenreich et al JACC 2022

34

2022 ACC/AHA/HFSA HF Guidelines



Heidenreich et al JACC 2022

35

ACC/AHA 2017 Guidelines for Treatment of HFpEF

Recommendations	COR	LOE
Systolic and diastolic blood pressure should be controlled according to published clinical practice guidelines	I	B
Diuretics should be used for relief of symptoms due to volume overload	I	C
Coronary revascularization for patients with CAD in whom angina or demonstrable myocardial ischemia is present despite GDMT	IIa	C
Management of AF according to published clinical practice guidelines for HFpEF to improve symptomatic HF	IIa	C
Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF	IIa	C
ARBs might be considered to decrease hospitalizations in HFpEF	IIb	B
In appropriately selected patients with HFpEF, aldosterone receptor antagonists might be considered to decrease hospitalizations	IIb	B-R


Heidenreich et al JACC 2022

36

Finerenone: FINEARTS-HF

- Finerenone VS Placebo in LVEF $\geq 40\%$
- NYHA II – IV

Figure. Kaplan-Meier Curve for Total Heart Failure Events and Cardiovascular Death




Solomon et al NEJM 2024
Pabon et al JAMA Card 2025

37

Device Therapy

38

CHAMPION TRIAL CardioMEMS




Abraham et al. Lancet 2011;377:658-66

39

CHAMPION Trial HF Hospitalization

N=550 NYHA III, 22% HFpEF



Abraham et al. Lancet 2011;377:658-66

40


CHAMPION – Results

	Not enrolled (n=25)	Treatment group (n=270)	Control group (n=280)	All patients (n=575)	Risk (95% CI)	p value	NNT
Primary efficacy endpoints*							
Heart-failure-related hospitalisations up to 6 months (number; events per patient per 6 months)	NA	84 (0.32)	120 (0.44)	NA	0.72† (0.60-0.85)	0.0002	8
Primary safety endpoints‡							
Device-related or system-related complications	2 (8%)	3 (1%)	3 (1%)	8 (1%)	§	<0.0001	NA
Pressure-sensor failures	0	0	0	0	§	<0.0001	NA
Prespecified supplementary efficacy endpoints¶							
Heart-failure-related hospitalisations during entire randomised follow-up	NA	158	254	NA	0.63† (0.52-0.77)	<0.0001	4
Secondary efficacy endpoints							
Change from baseline in pulmonary artery mean pressure at 6 months (mm Hg; days; mean area under the curve)	NA	-156	33	NA	NA	0.008	NA
Patients admitted to hospital for heart failure at 6 months	NA	55 (20%)	80 (29%)	NA	0.71 (0.53-0.96)	0.03	NA
Days alive outside hospital at 6 months (mean, SD)	NA	174.4 (31.1)	172.1 (37.8)	NA	NA	0.02	NA
Minnesota Living with Heart Failure Questionnaire at 6 months (mean, SD)	NA	45 (26)	51 (25)	NA	NA	0.02	NA

Abraham et al. Lancet 2011;377:658-66

41

Remote PA Monitoring Waveforms




FDA approved for wirelessly measuring and monitoring pulmonary artery (PA) pressure and **heart rate** in New York Heart Association (NYHA) **Class III HF** (HFrEF or HFpEF) patients who have been hospitalized for **HF** in the previous year

Abraham et al. Lancet 2011;377:658-66

42

Wireless PA Monitoring: Real World Experience



Desai, A.S. et al. J Am Coll Cardiol. 2017;69(19):2357-65.

43

Guide-HF

- 3/15/2018- 12/20/2019,
- 1022 patients were enrolled
- 1000 patients implanted successfully
- Follow-up completed on Jan 8, 2021
- Hemodynamic Arm
 - 253 out of 497 pts (0.563 per pt-yr)
- Control Group
 - 289 out of 503 pts (0.640 per patient-year) HR 0.88, 95% CI 0.74–1.05; p=0.16

Lindenfeld J, Zile MR, Desai AS, Bhatt K, Ducharme A, Horstmanshof D, Krim SR, Maisel A, Mehra MR, Paul S, Sears SF, Sauer AJ, Smart F, Zughaib M, Castaneda P, Kelly J, Johnson N, Sood P, Ginn G, Henderson J, Adamson PB, Costanzo MR. Hemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet. 2021 Sep 11;398(10304):991-1001. doi: 10.1016/S0140-6736(21)01754-2. Epub 2021 Aug 27. PMID: 34461042.

44

Guide-HF

Full Study
Results

Pre-COVID





Figure 2: Cumulative hazard rate curves and 95% CIs for the primary composite endpoint and heart failure hospitalisations
 (A) Overall analysis—primary outcome of all-cause mortality, heart failure hospitalisations, and urgent heart failure visits. (B) Overall analysis—heart failure hospitalisations. (C) Pre-COVID-19 impact analysis—primary outcome of all-cause mortality, heart failure hospitalisations, and urgent heart failure visits. (D) Pre-COVID-19 impact analysis—heart failure hospitalisations. HR=hazard ratio.


Lindenfeld et al. Lancet 2021

45



Lindenfeld et al. Lancet 2021

46



47

Guide HF-Pandemic Influence

Overall results found no significant reduction in the cumulative incidence of primary endpoint events

When adjusted for the COVID-19 pandemic, a significant decrease was observed in the pre-COVID-19 impact analysis

Primary Event Pre-Covid

- Hemodynamic Group: 177 primary events
- Control Group 224 events

Lindenfeld et al. Lancet 2021

48

Exercise Training

49

HFpEF Exercise Training Trials Summary

Name	N	Mo	Diast Fx	ET Type	Results
Kitzman et al 2010	53	4	N/A	Aerobic	Improved exercise capacity (VO ₂ peak, workload, exercise time) and submaximal exercise performance (VAT, 6MWT). Increased HR peak, HRR, O ₂ pulse. Improved physical score of MLHFQ
Edelman et al 2011	64	3	Grade ≥1	Both	Improved exercise capacity (VO ₂ peak, workload, exercise time) and submaximal exercise performance (VAT, 6MWT). Improved E/e'. Decreased LAVI. Improved SF-36 and MLHFQ scores. Reduced procollagen type 1 blood levels
Smart et al 2012	30	4	Delayed relax or Psnl	Aerobic	Increased exercise capacity (VO ₂ peak, workload). Increased CO. Improved strain rate, SV, and CO, in patients with >10% increase in VO ₂ peak
Haykowsky et al 2012	40	4	N/A	Aerobic	Improved exercise capacity (VO ₂ peak). Increased HRpeak, HRR. Increased estimated peak and reserve A-VO ₂ Diff and peak and reserve circulatory power
Fujimoto et al 2012	20	12	N/A	Aerobic	Improved E/A ratio
Kitzman et al 2013	63	4	N/A	Aerobic	Improved exercise capacity (VO ₂ peak, workload, exercise time) and submaximal exercise performance (VAT, 6MWT). Increased HRpeak, Improved SF-36 score

50

Higher Cardiorespiratory Fitness Predicts Long-term Survival in Patients with Heart Failure & Preserved Ejection Fraction The Henry Ford Exercise Testing (FIT) Project

Results:

- Mean age was 64 ±13 years, with 55% women, and 46% Black
- Over a median follow-up of 9.7 (5.2–18.9) years, there were 103 deaths
- In fully adjusted models, **moderate-high CRF was associated with 63% lower mortality risk (HR = 0.37, 95% CI: 0.18–0.73)** compared to the poor-CRF group
- In the propensity-matched cohort, HFpEF was associated with a HR of 2.3 (95% CI: 1.7–3.2) for mortality compared to non-HFpEF patients, which was attenuated to 1.8 (95% CI: 1.3–2.5) after adjusting for CRF

Orimoloye o, Kambhampati S, **Hicks A** et.al *Arch Med Sci* 2019

51

Higher Cardiorespiratory Fitness Predicts Long-term Survival in Patients with Heart Failure & Preserved Ejection Fraction The Henry Ford Exercise Testing (FIT) Project

Mortality Rates of the Study Population with HFpEF Stratified by METs Category

Death	Total, n, %	1–4 METs, n, %	5–6 METs, n, %	≥ 7 METs, n, %	P-value
At 1 year	10, 6.0	7, 7.8	3, 9.1	0, 0	0.14
At 2 years	17, 10.2	13, 14.4	4, 12.1	0, 0	0.03
At 3 years	26, 15.6	20, 22.22	5, 15.2	1, 2.3	0.01
At 4 years	31, 18.6	25, 27.8	5, 15.2	1, 2.3	0.001
At 5 years	40, 24.0	32, 35.6	6, 18.2	2, 4.6	< 0.001
At 7 years	59, 35.3	41, 45.6	13, 39.4	5, 11.4	< 0.001
At 10 years	78, 46.7	50, 55.6	16, 48.5	12, 27.3	0.008

Orimoloye o, Kambhampati S, **Hicks A** et.al *Arch Med Sci* 2019

52

Amyloid Cardiomyopathy

53


Amyloid the Great Confounder

- Many HFpEF studies may be neutral due to high number of unknown patients with cardiac amyloid confounding the outcomes
- Patients with amyloid traditionally do not tolerate GDMT for HF

Oghina S. et al. J Am Coll Cardiol HF. 2021;9(3):169-78.

54

Left Ventricular Amyloid Deposition in Patients with HFpEF



Mohammed et al. JACC HF 2014

55


Common Amyloid Types

Protein Class	Precursor Protein	Amyloid Type	Clinical Type
High Density Apolipoproteins	Serum Amyloid A protein	AA	Amyloid complicating chronic infections, inflammatory diseases, and some familial periodic fever syndromes (Mediterranean fever). Serum Amyloid A is an acute phase reactant.
Immunoglobulin (Ig)	Ig Light chain	AL	Myeloma Associated
Transport Protein	Transthyretin (TTR; prealbumin)	ATTRmt ATTRwt	Amyloid involving cardiac, renal, and nervous system caused by normal TTR tissue deposition over time (Wild Type) or from TTR gene point mutation

Adapted from UpToDate 2021

56

ATTR Pathophysiology



Ruberg et al JACC 2019

57

ATTR Cardiac Amyloidosis


- ATTR Wild Type (ATTRwt) is most common transthyretin amyloidosis, with genetically unaltered deposition of transthyretin in body tissues after the 6th decade of life
- ATTR mutation (ATTRmt) involves a point mutation of the transthyretin gene resulting in a substitution of isoleucine for valine at position 122 (Val122Ile)

Cornwell GG, Murdoch WL, Kyle RA, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. *Am J Med.* 1983; 75:618–623.

Shah KB, Mankad AK, Castano A, Akinboboye OO, Duncan PB, Fergus IV, Maurer MS. Transthyretin Cardiac Amyloidosis in Black Americans. *Circ Heart Fail.* 2016 Jun;9(6):e002558. doi: 10.1161/CIRCHEARTFAILURE.115.002558. PMID: 27188913; PMCID: PMC4874558.

58


ATTRmt-CM Genotype



Poli L, et al. *Front Neurol.* 2023;14:1242815. 2. Griffin JM, et al. *JACC CardioOncol.* 2021;3(4):488-505. 3. Buxbaum JN, Ruberg FL. *Genet Med.* 2017;19(7):733-742.

59


Tafamidis Reduces Mortality TTR in Amyloid Cardiomyopathy



Maurer et al. *NEJM* 2018

60

Prevalence of ATTR-CM in Other Conditions



AS, aortic stenosis; LVWT, left ventricular wall thickness; TAVR, transcatheter aortic valve replacement.

1. Castaño A, et al. *Eur Heart J*. 2017;38(38):2879-2887. 2. González-López E, et al. *Eur Heart J*. 2015;36(38):2585-2594. 3. Hahn VS, et al. *JACC Heart Fail*. 2020;8(9):712-724. 4. Sperry BW, et al. *J Am Coll Cardiol*. 2018;72(17):2040-2050. 5. Brito D, et al. *Glob Heart*. 2023;18(1):59. 6. Damy T, et al. *Eur Heart J*. 2016;37(23):1826-1834. 7. AbouEzzeddine OF, et al. *JAMA Cardiol*. 2021;6(11):1267-1274. 8. Quarta CC, et al. *N Engl J Med*. 2015;372(1):21-29. 9. Shah KB, et al. *Circ Heart Fail*. 2016;9(6):e002558.

61

ATTRmt Cardiac Amyloidosis

ATTRmt Cardiac Amyloid is a great mimicker

- HTN Heart Disease
- Hypertrophic Cardiomyopathy

Approximately 4% of African Americans in the US carry the Val122Ile mutation

Diagnosis tends to occur late in disease course and involve multiple organ systems (Cardiac, Nervous System, Renal)


62

UMMC AL Amyloidosis Diagnostics

- Serum Kappa/Lambda Free Light Chain Assay
 - < 0.26 or > 1.65
 - Abnormality based on renal function
- Serum Immunofixation (Serum or Urine)
 - Detects for monoclonal proteins


63

UMMC Cardiac Amyloidosis Diagnosis Algorithm



64

Echocardiogram




- Diastolic Dysfunction
- Increased LV wall thickness >12 mm
- Thickening of valve leaflets and interatrial septum
- Pleural and pericardial effusion(s)
- Biatrial enlargement

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. PMID: 31171094; PMCID: PMC6724183.

65

Echocardiogram & Longitudinal Strain Patterns



ATTR CM


- > 2:1 apical:basal ratio or “cherry on top”
- Abnormal GLS < -15% (-10.3%)

No Amyloid

- Bullseye map shows absence of apical sparing
- Normal GLS < -15% (-21%)

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. PMID: 31171094; PMCID: PMC6724183.


66




Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. PMID: 31171094; PMCID: PMC6724183.

67

Pyrophosphate Scan for Cardiac ATTR





Positive scan: 97% sensitivity, 100% specificity for identifying ATTR cardiac amyloidosis ($p < 0.0001$)




Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidosis. *Circ Cardiovasc Imaging*. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11. PMID: 23400849; PMCID: PMC3727049.

68

Heart Biopsy



69



Endomyocardial Biopsy

A. Autopsy

- Biventricular Thickening
- Biatrial Dilation
- Thick of Mitral & Tricuspid valves

B. Congo red staining

- Hematoxylin & eosin staining

C. Polarized Light Microscopy

- Apple-Green birefringence


D. Immunohistochemistry

- Typing amyloid (AL VS ATTR)

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun 11;73(22):2872-2891. doi: 10.1016/j.jacc.2019.04.003. PMID: 31171094; PMCID: PMC6724183.

70

Strategy for Screening Amyloid in Clinical Trials



Oghina S. et al. J Am Coll Cardiol HF. 2021;9(3):169-78.

71

2022 ACC/AHA/HFSA Guidelines

COR	LOE	Recommendations
1	B-R	1. In select patients with wild-type or variant transthyretin cardiac amyloidosis and NYHA class I to III HF symptoms, transthyretin tetramer stabilizer therapy (tafamidis) is indicated to reduce cardiovascular morbidity and mortality. ¹
Value Statement: Low Value (B-NR)		2. At 2020 list prices, tafamidis provides low economic value (>\$180 000 per QALY gained) in patients with HF with wild-type or variant transthyretin cardiac amyloidosis. ²
2a	C-LD	3. In patients with cardiac amyloidosis and AF, anticoagulation is reasonable to reduce the risk of stroke regardless of the CHA ₂ DS ₂ -VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack [TIA], vascular disease, age 65 to 74 years, sex category) score. ^{3,4}


72

FDA Approved Therapies for HFpEF

- Empagliflozin (Class 2a)
- Spironolactone (Class 2b)
- Sacubitril-Valsartan (Class 2b)
- CardioMEMS
- Amyloid Therapy

73

2022 ACC/AHA/HFSA Guidelines



74

HFpEF SUMMARY

- SGLT2-I first line therapy for HFpEF
- Exercise Training is beneficial for QOL
- Fitness can predict long-term survival
- Rule out Amyloidosis in HFpEF patients
- Spironolactone in appropriate patients
- Sacubitril-Valsartan in lower EFs
- Consider CardioMems to reduce HHF
- Future Therapies